原发性乳腺癌：ESMO诊断、治疗及随访临床实践指南 - Suppr

Suppr

超能文献

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Aebi S, Davidson T, Gruber G, Cardoso F

机构信息

Division of Medical Oncology, Kantonsspital, Lucerne, Switzerland.

出版信息

Ann Oncol. 2011 Sep;22 Suppl 6:vi12-24. doi: 10.1093/annonc/mdr371.

DOI:10.1093/annonc/mdr371

PMID:21908498

Abstract

摘要

相似文献

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2011 Sep;22 Suppl 6:vi12-24. doi: 10.1093/annonc/mdr371.

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2011 Sep;22 Suppl 6:vi25-30. doi: 10.1093/annonc/mdr372.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2010 May;21 Suppl 5:v9-14. doi: 10.1093/annonc/mdq159.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep;26 Suppl 5:v8-30. doi: 10.1093/annonc/mdv298.

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2010 May;21 Suppl 5:v15-9. doi: 10.1093/annonc/mdq160.

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Ann Oncol. 2008 May;19 Suppl 2:ii7-10. doi: 10.1093/annonc/mdn071.

Recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Ann Oncol. 2007 Apr;18 Suppl 2:ii9-11. doi: 10.1093/annonc/mdm016.

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9. doi: 10.1093/annonc/mds232.

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Ann Oncol. 2007 Apr;18 Suppl 2:ii5-8. doi: 10.1093/annonc/mdm015.

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9. doi: 10.1093/annonc/mds253.

引用本文的文献

The Diagnostics of Disease Relapse Within Five-Year Follow-Up and the Role of Androgen Receptor Expression in Patients with Early Triple-Negative Breast Cancer.

Diagnostics (Basel). 2025 Mar 11;15(6):692. doi: 10.3390/diagnostics15060692.

Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment.

Discov Oncol. 2024 Dec 18;15(1):797. doi: 10.1007/s12672-024-01701-x.

The impact of lymphedema severity on shoulder joint function and muscle activation patterns in breast cancer survivors: a cross-sectional study.

Support Care Cancer. 2024 Dec 17;33(1):37. doi: 10.1007/s00520-024-09044-7.

Macrophages: Key Players in the Battle against Triple-Negative Breast Cancer.

Int J Mol Sci. 2024 Oct 7;25(19):10781. doi: 10.3390/ijms251910781.

The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pTNM breast cancer.

Radiat Oncol. 2024 Sep 13;19(1):120. doi: 10.1186/s13014-024-02510-w.

A case report and literature review on a rare subtype of triple-negative breast cancer in children.

BMC Pediatr. 2023 Sep 29;23(1):494. doi: 10.1186/s12887-023-04286-6.

Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer.

Drug Deliv Transl Res. 2023 Jun;13(6):1621-1653. doi: 10.1007/s13346-023-01299-7. Epub 2023 Feb 16.

Axillary nodal metastasis and resection margins as predictors of Loco Regional Recurrence in Breast Cancer Patients.

Afr Health Sci. 2022 Mar;22(1):115-124. doi: 10.4314/ahs.v22i1.15.

Synthesis and Evaluation of Technetium-99m-Labeled pH (Low) Insertion Peptide Variant 7 for Early Diagnosis of MDA-MB-231 Triple-Negative Breast Cancer by Targeting the Tumor Microenvironment.

Front Oncol. 2022 Apr 21;12:869260. doi: 10.3389/fonc.2022.869260. eCollection 2022.

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.

Breast. 2022 Aug;64:151-158. doi: 10.1016/j.breast.2022.03.001. Epub 2022 Mar 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验